

Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

- * Surname: _____
- * Given Name: _____
- * OHIN: _____ * Chart Number: _____
- * Postal Code: _____
- * Height (cm): _____ * Weight (kg): _____
- * BSA (m²): _____ * Gender: Male Female Other
- * Date of Birth: _____
Day Month Year
- * Site: _____
- * Attending Physician (MRP- Most Responsible Physician):
Requested Prior Approval Yes * Patient on Clinical Trial Yes No
- Other (specify): _____
- Specify Arm:
 Standard of care arm Experimental arm
 Blinded / Unknown

Request prior approval for enrolment

- * Justification for Funding

Anticipated date of first treatment

Day Month Year

2. Eligibility Criteria

The patient must meet the following criteria:

- a. The patient has in-transit metastases from melanoma Yes
- b. The patient has failed or is not a candidate for surgery or other treatments.

3. Funded Dose

- 1 vial (22 million IU) of aldesleukin will be funded per cycle for intralesional injection.
- As of December 21, 2016, the submission of claims has changed from vial to mU. The cost of the full vial (22 million IU) will be reimbursed according to the public reimbursement price.

4. Notes

1. NDFP funding is for patients who receive aldesleukin as an intralesional injection.
2. This drug may be referred to as aldesleukin or interleukin-2.

5. FAQs

- i. **My patient is currently receiving aldesleukin through private means. Can my patient be transitioned over to receive funding through the New Drug Funding Program?**

Provided the funding criteria were met at the time of treatment initiation, your patient may be eligible for continued coverage of aldesleukin through the New Drug Funding Program.

- ii. **My patient has started a chemotherapy regimen and I would like to switch them to aldesleukin. Would NDFP allow this switch?**

The decision to switch should be based on a discussion between the clinician and patient. Provided your patient meets the funding criteria, NDFP will fund the aldesleukin after the switch.

6. Supporting Documents

None required for this policy.

In the absence of collecting supporting documentation at the time of enrolment:

- CCO reserves the right to perform an audit of patient eligibility.
- In the event of an audit, CCO may request the following:
- A clinic note stating that the patient has in-transit metastases.

Signature of Attending Physician (MRP-Most Responsible Physician):

.....
Day Month Year